Mirogabalin Besylate: Brands, Price & Uses in Bangladesh

Mirogabalin Besylate is a gabapentinoid (alpha-2-delta calcium channel ligand) used in the management of neuropathic pain. Its use can be classified by strength of evidence as follows:

Established / Guideline-Supported Uses

• Peripheral neuropathic pain, including diabetic peripheral neuropathic pain (DPNP) - an approved indication for Mirogabalin Besylate in several Asian regulatory markets, based on randomized controlled trials.
• Postherpetic neuralgia (PHN) - pain persisting after resolution of herpes zoster (shingles) rash, an approved indication for Mirogabalin Besylate where the drug is registered.

Regulatory Status

Mirogabalin Besylate is approved and marketed in Japan, South Korea, and other Asian markets (including Bangladesh) for peripheral neuropathic pain. It does not currently hold FDA approval in the United States; prescribing decisions outside markets where it is registered should follow local regulatory labeling.

As with other gabapentinoids, Mirogabalin Besylate should be used only for indications supported by a physician's assessment of the patient's pain condition; it is not indicated for nociceptive (non-neuropathic) pain.

Adults with Normal Renal Function

• Initial dose: 5 mg orally twice daily.
• Titration: Increase in increments of 5 mg per dose at intervals of one week or more, based on response and tolerability.
• Usual maintenance dose: 10 mg to 15 mg twice daily.

Dose Adjustment in Renal Impairment

Mirogabalin Besylate is renally cleared, and dose adjustment based on creatinine clearance (CLcr) is required:

Titration in renal impairment should proceed cautiously and more slowly than in patients with normal renal function, guided by physician judgment.

Administration

Mirogabalin Besylate tablets may be taken with or without food, generally with a glass of water, at approximately the same times each day (e.g., morning and evening) to maintain steady drug levels. Tablets should be swallowed whole and not crushed or chewed unless a physician or pharmacist advises otherwise. Mirogabalin Besylate should not be stopped abruptly; if discontinuation is needed, the dose should be tapered gradually over at least one week under medical supervision to reduce the risk of withdrawal-like symptoms (see Precautions and Warnings).

Adverse effects of Mirogabalin Besylate are generally dose-related and most prominent during titration.

Common

• Somnolence (sleepiness) and dizziness
• Peripheral edema (swelling of hands, ankles, or feet)
• Weight gain
• Constipation
• Blurred or double vision

Less Common but Clinically Important

• Headache, tremor, memory impairment, or unsteady gait
• Orthostatic hypotension (dizziness on standing)
• Rare reports of loss of consciousness
• Hallucinations or confusion (more common in elderly patients)
• Signs of liver dysfunction (yellowing of skin/eyes, dark urine) - rare but requires prompt evaluation

Patients should seek medical attention promptly for severe dizziness, fainting, difficulty breathing, signs of an allergic reaction, or signs of liver problems while taking Mirogabalin Besylate.